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Factor VIII (FVIII), a plasma glycoprotein, is an essential cofactor in the blood coagulation cascade. It is a multidomain protein, known to
bind to phosphatidylserine (PS)-containing membranes. Based on X-ray and electron crystallography data, binding of FVIII to PS-containing
membranes has been proposed to occur only via the C2 domain. Based on these models, the molecular topology of membrane-bound FVIII
can be envisioned as one in which only a small fraction of the protein interacts with the membrane, whereas the majority of the molecule is
exposed to an aqueous milieu. We have investigated the topology of the membrane-bound FVIII using biophysical and biochemical
techniques. Circular dichroism (CD) and fluorescence studies indicate no significant changes in the secondary and tertiary structure of FVIII
associated with the membranes. Acrylamide quenching studies show that the protein is predominantly present on the surface of the
membrane, exposed to the aqueous milieu. The light scattering and electron microscopy studies indicate the absence of vesicle aggregation
and fusion. Binding studies with antibodies directed against specific epitopes in the A1, A2 and C2 domains suggest that FVIII binds to the
membrane primarily via C2 domain including the specific phospholipid binding epitope (2303–2332) and may involve subtle conformational
changes in this epitope region.
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Sandwich ELISA1. Introduction
Factor VIII (FVIII) is an important plasma glycoprotein
involved in the blood coagulation cascade. Deficiency of
FVIII causes hemophilia A, an X-linked genetic bleeding
disorder [1]. FVIII is a heterodimeric, multidomain protein
of approximately 280,000 Da molecular weight consisting
of a heavy chain and a light chain (Fig. 1a). It is synthesized
as a 2351-residue single chain precursor protein consisting
of A1–A2–B–A3–C1–C2 domains. A 19-residue signal-
ing peptide is cleaved prior to the translocation of the0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2003.08.012
Abbreviations: FVIII, factor VIII; PS, phosphatidylserine; DMPC,
dimyristoyl phosphatidylcholine; PBT, phosphate buffer with Tween 20;
PB, phosphate buffer; CD, circular dichroism; aPTT, activated partial
thromboplastin time; TB, Tris buffer
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further cleaved to form the heavy chain (A1–A2) and light
chain (A3–C1–C2) in the Golgi [2–5]. The cleaved protein
consists of multiple polypeptides with molecular weight
ranging from 70 to 230 kDa. The amino acid sequence
indicates that 230 and 70 kDa peptides represent the
carboxy (heavy chain) and amino (light chain) terminals,
respectively (Fig. 1).
In the coagulation cascade, FVIII upon activation by
thrombin, forms activated FVIII (FVIIIa) in which the
FVIII molecule is cleaved into heavy (A1–A2 domains)
and light (A3–C1–C2 domains) chains. Both FVIII and
FVIIIa are known to bind to phosphatidylserine (PS)-rich
membranes of the platelets via the C2 domain [6,7] with
similar binding characteristics [8], but FVIIIa displays
higher affinity [9,10].
The structure of the C2 domain has been solved by X-
ray crystallography where two hydrophobic beta hairpin
 Fig. 1. (a) Schematic representation of the domain structure of FVIII and the monoclonal antibodies recognizing different epitopes. (b) SDS-PAGE of silver-
stained plasma-derived FVIII (pdFVIII) and recombinant FVIII (rFVIII). (c) Size exclusion chromatogram of recombinant FVIII. vWF—vonWillebrand factor.
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been proposed as the membrane binding epitopes [11].
Site-directed mutagenesis studies have confirmed the in-
volvement of the above four amino acid residues [6].
Recently, based on 1.5-nm resolution, 2-D electron crys-
tallography studies, it has been proposed that four hydro-
phobic loops in the C2 domain (2222–2227, 2196–2201,
2313–2315 and 2249–2255) are involved in binding to
membranes [8]. In this model, the involvement of 2313–
2315 has been suggested in addition to two hydrophobic
hairpin turns proposed by Pratt et al. [11]. Further, this
model suggests that a major part of the protein is not
involved in the interaction with the membranes (Fig. 2).
Since the binding of FVIII to activated platelet surfaces is
essential for its activity [12], understanding the conforma-
tion and topology of FVIII bound to membranes would
shed light on the structure–function relationship of this
multidomain protein. In order to investigate the molecular
topology of FVIII bound to membranes, we utilized bio-
physical and biochemical techniques and the results suggest
that FVIII binds to PS-containing membranes primarily viathe C2 domain with only subtle changes in the conforma-
tion of the protein.2. Materials and methods
2.1. Materials
The monoclonal antibodies ESH4, ESH5 and ESH8 were
obtained from American Diagnostica (Greenwich, CT) and
8860 was a gift from Baxter (Duarte, CA). Avidin alkaline
phosphatase conjugate and IgG-free bovine serum albumin
was obtained from Sigma (Saint Louis, MO). Recombinant
FVIII was expressed either in Chinese hamster ovary (CHO)
cell line or in Cos-7 cells and was chromatographically
purified as described previously [13–16]. The protein was
characterized by SDS-PAGE (Fig. 1b) and high performance
size exclusion chromatography (HP-SEC) (Fig. 1c). The
recombinant protein thus obtained is similar to the plasma-
derived FVIII as shown in Fig. 1b, where both display
multiple polypeptide bands in the range of 230–70 kDa
Fig. 2. The proposed molecular model for membrane-bound FVIII. The
figure was reconstructed using Rasmol (Ver. 2.7.2.1) based on the
coordinates available at http://europium.csc.mrc.ac.uk.
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phosphatidylserine (BPS) were obtained from Avanti Polar
Lipids (Alabaster, AL) and were used without further
purification. p-Nitrophenyl phosphate disodium salt was
obtained from Pierce (Rockford, IL). All other buffer salts
and solvents used in the study were obtained from Fisher
Scientific (Fairlawn, NJ) and were used without further
purification.
2.2. Biological activity assay of FVIII
The clotting activity was determined by one-stage
activated partial thromboplastin time (aPTT) assay using
micronized silica as activator (Organon Teknika Corpora-
tion, Durham, NC) and FVIII-deficient plasma (Biopool
International, Ventura, CA) as the substrate [18]. The assay
was performed using COAG-A-MATE coagulation analyz-
er (Organon Teknika). FVIII was added to FVIII-deficient
plasma and the clotting time was monitored. The activity
and concentration of the protein was obtained using
calibration curve generated using lyophilized reference
standards (6th International Standard, NIBSC, Hertford-
shire, UK).
2.3. SDS-PAGE and HP-SEC
Silver-stained sodium dodecyl sulfate-polyacrylamide
gel electrophoresis gels (SDS-PAGE) were run according
to the procedure of Laemmli (Biorad, Hercules, CA) [19].
HP-SEC was performed using Biosep SEC S4000 4.6 300
mm analytical column. Chromatograph comprised of a
Waters 510 HPLC Pump, Rheodyne injector with a 50-Al sample loop and Hitachi F1050 fluorescence detector.
Excitation and emission were set at 285 and 330 nm,
respectively, to monitor the elution of the protein. Gel
filtration was carried out under isocratic conditions at a
flow rate of 0.4 ml/min using an aqueous buffer consisting
of 5 mM Tris, 5 mM CaCl2 and 300 mM NaCl, pH 7.4.
2.4. Preparation of membrane-associated FVIII
Membrane vesicles were prepared by rehydrating a thin
film of appropriate molar ratios of DMPC and BPS (70:30)
with Tris buffer (TB) (25 mM Tris, 5 mM CaCl2 and 300
mM NaCl, pH = 7.0). The thin film was prepared by mixing
DMPC and BPS in chloroform in a small round bottom
flask or kimax tube and evaporating the solvent in a Rota-
evaporator (Buchi R-200, Fischer Scientific, NJ). The mem-
brane vesicles were sized by extruding through a 200-nm
cutoff polycarbonate membrane in a high-pressure extruder
(Lipex Biomembranes Inc., Vancouver, Canada) at a pres-
sure of f 250 psi. The sized membrane vesicles were
associated with FVIII (150 Ag) by incubating at 37 jC with
gentle swirling for f 30 min. The molar ratio between the
lipid and the protein was maintained at 10,000:1 (5.35 mM:
0.535 AM) for all experiments, respectively. Use of sized
membrane vesicles with a fixed size to charge ratio ensured
reproducible association of FVIII to membrane vesicles. In
this isolated system, it is assumed that the location of the
protein on the inner leaflet of the vesicles is minimal. The
membrane-associated FVIII was analyzed immediately or
within 24 h after storage at 4 jC.
2.5. Separation of free protein from membrane-bound
The free protein was separated from the membrane-
bound protein by dextran density gradient ultracentrifuga-
tion [20]. Briefly, the membrane vesicle/protein mixture
(0.5ml) was mixed with 1 ml of 20% (w/v) dextran in TB
and placed in a 5 ml polypropylene tube with 3 ml of 10%
(w/v) dextran, followed by 0.5 ml buffer (0% dextran)
layered over it. The gradient column was ultracentrifuged
at 45,000 rpm for 30 min in Beckman SW 50.1 rotor. The
membrane-associated protein floated to the interface of 0%
dextran buffer and 10% dextran layer leaving the unassoci-
ated protein in the bottom dextran layer. The percentage of
activity associated with the membranes was determined by
the one-stage aPTT method [18].
2.6. Determination of particle size of membrane vesicles
Particle size of the membrane vesicles were determined
by dynamic light scattering using a Nicomp Model CW
380 particle size analyzer (Particle Sizing Systems, Santa
Barbara, CA) both before and after association with the
protein. The instrument was calibrated using 0.258-Am
standard latex beads. All measurements were carried out
at a temperature of 23 jC with viscosity and refraction
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fitted to an intensity weighted Gaussian curve to determine
the distribution.
2.7. Circular dichroism (CD) studies
CD spectra were acquired on a JASCO-715 spectropo-
larimeter calibrated with d-10 camphor sulfonic acid. Sam-
ples were scanned in the range of 255–208 nm for
secondary structural analysis using a 2 mm quartz cuvette
and typically, the protein concentration used was 20–22 Ag/
ml. CD spectra of the protein in the presence and absence of
membrane vesicles were corrected by subtracting the spectra
of buffer and protein-free liposomes. Multiple scans were
acquired and averaged to improve the signal quality.
2.8. Fluorescence spectroscopy and acrylamide quenching
Emission spectra of FVIII and membrane-associated
FVIII were obtained using PTI fluorometer (QuantaMaster,
Photon Technology International, Lawrenceville, NJ). The
samples were excited at 280 nm and the emission spectrum
was obtained from 300 to 400 nm. A slit width of 4 nm was
used on both the excitation and emission paths.
For fluorescence quenching experiments, the samples
were excited at 280 nm and the emission was monitored
at 335 nm for FVIII and 333 nm for membrane-bound
FVIII. A small shoulder observed at f 310 nm in the
spectrum of membrane-associated FVIII was due to Raman
scattering. This was confirmed by exciting the sample at 265
nm, which resulted in the disappearance of the shoulder.
Studies were carried out at 20 jC using a slit width of 4 nm
on the excitation and emission paths. In order to minimize
the contribution due to inner filter effect for samples
containing acrylamide, an ‘‘I-shaped’’ cuvette with two
different path lengths was used to acquire the fluorescence
emission spectra [21]. The protein concentration was typi-
cally 5 Ag/ml in TB. Quenching was monitored following
successive addition of aliquots of 5 M acrylamide stock
solution. The data were analyzed according to the classical
Stern–Volmer relationship [21].
2.9. Sandwich ELISA
Sandwich ELISA utilizes an immobilized antibody
against a specific epitope as a capture antibody and a
different, non-overlapping antibody as the probe antibody,
which is biotinylated. The probe antibody recognizes epit-
opes that are different from capture antibody. The advan-
tages of the sandwich ELISA over simple antibody capture
ELISA is that this technique allows both the membrane-
bound and the free protein to be in solution rather than
bound to surface of the ELISA plate. In the latter case,
membrane-bound FVIII may have different binding charac-
teristics compared to free FVIII and the amount of FVIII
localized on the plate can be a confounding variable. Thesandwich ELISA assumes that the protein–membrane in-
teraction is stronger than antibody-protein binding.
Nunc-Maxisorb 96-well plates were coated with ESH4/
8860 antibody by incubating 50 Al/well solution of the
antibody at a concentration of 5 Ag/ml in carbonate buffer
(0.2 M, pH= 9.4) overnight at 4 jC. The plate was then
washed 10 times with 100 Al of phosphate buffer containing
0.05% Tween 20 (PBT consisting of 10 mM Na2HPO4, 1.8
mM KH2PO4, 0.14 mM NaCl, 2.7 mM KCl, and 0.02%
NaN3). The remaining nonspecific protein binding sites on
the adsorptive surface of the plastic were blocked by
incubating 200 Al of blocking buffer consisting of 1%
bovine serum albumin in phosphate buffer (PB consisting
of 10 mM Na2HPO4, 1.8 mM KH2PO4, 0.14 mM NaCl, and
2.7 mM KCl) for 2 h at room temperature. The plates were
washed 10 times with PBT and 50 Al of 100 ng/ml of FVIII
or membrane-associated FVIII in blocking buffer was added
and incubated at 37 jC for 1 h. The plates were washed 10
times with PBT and incubated with 50 Al of biotinylated
ESH8/ESH5 at 1 Ag/ml concentration and 50 Al of a 1:1000
dilution of avidin-alkaline phosphatase conjugate, both in
blocking buffer at room temperature for 1 h. The plates were
washed 10 times with PBT and 100 Al of 1 mg/ml p-
nitrophenyl phosphate solution in diethanolamine buffer
(consisting of 1 M diethanolamine, 0.5 mM MgCl2 and
0.02% NaN3) was added. The plates were incubated at room
temperature for 30 min and the reaction was quenched by
adding 100 Al of 3 N NaOH. Absorbance was read at 405
nm using a plate reader.3. Results and discussions
3.1. Association of FVIII with membranes
The characterization of membrane binding properties of
FVIII has been the focus of several studies [22–24].
Bardelle et al. [23] have shown that the binding of FVIII
to membrane is biphasic with a surface adsorption step
followed by specific binding. The dissociation also occurs
in a biphasic manner. It has been shown that the binding of
FVIII is dependent on the concentration of lipid [23,25]. In
larger vesicles (>200 nm lipid particles) approximately 29
lipid molecules are involved per protein. In vitro binding
studies have shown that the binding saturates at a lipid
composition of f 30% PS [23,24]. Therefore, based on
previous studies, the membrane-bound protein was obtained
using a lipid composition of DMPC/BPS (70:30) and the
protein–lipid mixture was equilibrated for 30 min to pro-
mote specific interaction between protein and membrane, as
described in Section 2.4. The fraction of protein bound to
membranes was separated from the free, and possibly
surface-adsorbed FVIII, using gradient centrifugation. It
was found that 45.2% (F 16.8, n = 16) of the activity was
associated with the membrane fraction that floated based on
the aPTT and spectroscopic assay. The conformation and
Fig. 3. Secondary structure of FVIII associated with membranes
(MemFVIII): the far UV CD spectra of free and membrane-bound FVIII
was acquired in the range of 255–208 nm. Typically, the concentration of
the protein used was f 20–22 Ag/ml and the path length of quartz cuvette
was 2 mm. The vertical bars indicate the noise level in the spectral
measurement.
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fractions of the centrifugation gradient and the concentration
of the protein was corrected based on activity assay of the
membrane-bound fraction.1
3.2. Conformation of membrane-associated FVIII
The secondary and tertiary structural changes of mem-
brane-bound FVIII were studied by CD and fluorescence
spectroscopy, respectively.
Far UV CD (255–208 nm) was used to monitor the
changes in the secondary structure of the free protein and
protein associated with membranes (Fig. 3). The CD
spectrum acquired for free FVIII showed a broad nega-
tive band at 215 nm, indicating that the protein exists
predominantly in the h-sheet conformation. The addition
of membrane vesicles did not result in significant changes
in the spectral characteristics. Apart from small changes
in intensity, a similar broad negative band was also1 The centrifugation step may interfere with the membrane binding
equilibrium. Centrifugation step depletes the available free protein and
possibly the protein that is adsorbed to the membrane surface. The protein-
vesicle complex in the floated fraction may reestablish the equilibrium by
generating a small fraction of free FVIII. In order to determine the
contribution of centrifugation, the biophysical and biochemical studies were
carried out before and after the centrifugation step as control. In general, the
results indicated that the conformation and topology was similar before and
after centrifugation step except that the % of protein associated with the
membrane decreased as a result of centrifugation.observed for the FVIII bound to membrane that was
separated from free protein. Overall, the data suggests
that the membrane binding does not result in significant
alteration(s) in the secondary structure of the protein. The
small decrease in intensity could be due to variation in
estimation of concentration of membrane-bound protein
based on activity assay. It is known that determination of
activity by one-stage aPTT assay is sensitive to phospho-
lipid concentration [26].
Tertiary structural changes in the protein were investi-
gated by fluorescence spectroscopy (Fig. 4). The emission
spectrum of membrane-free FVIII showed an emission
maximum of 335 nm [27] and the addition of PS-
containing membranes resulted in a small blue shift in
the emission maxima to 333 nm that is accompanied by a
small increase in intensity. If the binding of the protein to
membrane vesicles were mediated by substantial interca-
lation or encapsulation of hydrophobic domains, the
spectral properties would indicate a pronounced blue shift
associated with a substantial increase in quantum yield.
However, modest changes in the emission spectrum
indicate that there are only minimal conformational
changes and the majority of the protein in the mem-
brane-bound form is in an environment comparable to
free protein.
3.3. Acrylamide quenching studies of membrane-bound
FVIII
The molecular topology consistent with little conforma-
tional change is that the contact between the protein andFig. 4. Tertiary structure of FVIII associated with membrane (MemFVIII):
fluorescence emission spectra of free membrane-associated FVIII was
acquired in the range of 300–400 nm. The excitation monochromator was
set at 280 nm. The protein concentration used was 5 Ag/ml.
Fig. 5. Acrylamide quenching of FVIII and membrane-bound FVIII
(MemFVIII): Stern–Volmer plots were obtained by plotting C0 /C vs. Q.
The samples were excited at 280nm and the emission was monitored at 335
nm (FVIII) and 333 nm (MemFVIII). Quenching was achieved by using
acrylamide over the concentration range of 0–0.5 M. The protein
concentration was typically 5 Ag/ml, and an I-shaped cuvette with varying
path lengths was used to minimize inner filter effects.
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on this observation, it is anticipated that a large fraction of
the protein surface is accessible to aqueous medium and
membrane provides only modest shielding of the fluorescent
residues such as Trp. Therefore, the addition of collisional
quenchers would result in comparable loss of Trp fluores-
cence intensity for both free and membrane-bound FVIII. In
order to investigate the accessibility of fluorophores in the
protein, collisional quencher acrylamide was added to the
membrane-bound FVIII (Fig. 5). As is clear from the figure,
the addition of increasing concentration of acrylamide
quenches the Trp fluorescence of both free and mem-
brane-bound FVIII. The extent of quenching is slightly
lower for the membrane-bound protein, suggesting that only
a small fraction of the protein molecule is inaccessible to
quenchers. The modified Stern–Volmer plot was used to
evaluate the number of Trp residues accessible to collisional
quenchers (data not shown). The preliminary data indicates
that the fraction of accessible Trp residues decreases byTable 1
Particle size analysis of PS-containing membrane vesicles in the presence and ab
Trial Membrane vesicles
Mean size Standard deviation Chi-square Distribution
1 221.2 102.9 0.43 Gaussian
2 225.4 101.4 0.89 Gaussian
3 224.6 94.8 0.59 Gaussianapproximately 5–10%. FVIII has 36 Trp residues and the
semi-quantitative estimation based on quenching data indi-
cates that probably two to four Trp residues may be
inaccessible to the quencher as a result of membrane
binding. It is appropriate to mention here that, the above
interpretation assumes that all 36 Trp residues spanning the
various domains of FVIII contribute equally to the intrinsic
fluorescence of the protein.
3.4. Membrane fusion and aggregation
It has been well documented that PS-containing vesicles
fuse and aggregate in the presence of Ca2 + ions [28]. In
order to investigate whether vesicle fusion or aggregation
influence the determination of molecular topology of mem-
brane-bound FVIII as our buffer system contained 5 mM
Ca2 +, we performed dynamic light scattering and electron
microscopic studies. The size of the vesicles was measured
before and after the addition of protein. The vesicles
formed after extrusion showed that the distribution of
particle size is Gaussian with a mean particle diameter of
223.73 nm (Table 1). The chi-squared values indicated the
particle distribution is homogeneous. The addition of pro-
tein did not result in significant change (two-sample t-test,
P-value = 0.8785) in the particle size suggesting that mem-
brane fusion and aggregation is minimal. This is further
confirmed by negative stain electron microscopic studies
(data not shown). The absence of vesicle fusion may be due
to the presence of large excess of PC and NaCl and is
consistent with the observations of Duzgunes et al. [28]. A
critical ratio of 0.35 of Ca bound per molecule of PS (Ca/
PS) was reported to be necessary for the Ca2 +-mediated
destabilization and vesicle fusion. However, this destabili-
zation was found to be dependent on the bulk Na+
concentration. High Na+ concentration (as is the case here)
inhibits Ca2 +-induced fusion of PS vesicles by reducing the
critical ratio of Ca/PS. Similarly, presence of PC at >50
mol% was also found to interfere with Ca2 +-induced
destabilization.
3.5. Sandwich ELISA
Based on the models proposed by X-ray [11] and
electron diffraction studies [8], it has been proposed that
the protein binds to membranes via C2 domain. The spectral
studies were consistent with this model in which there are
minimal or no conformational changes upon binding ofsence of FVIII
FVIII-associated membrane vesicles
Mean size Standard deviation Chi-square Distribution
213.5 102.7 2.440 Gaussian
266.7 136.8 1.840 Gaussian
200.7 83.50 1.861 Gaussian
Fig. 6. Antibody binding to FVIII and membrane-associated FVIII
(MemFVIII) as determined by sandwich ELISA: binding of ESH4 (C2
domain 2303–2332) and ESH8 (C2 domain 2248–2285).
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of C2 domain in membrane binding, we performed sand-
wich ELISA, a functional assay to probe the specific
domains and amino acids that participate in membrane
interaction (Fig. 6).
Sandwich ELISA is a screening technique that uses
antibody binding to probe epitope sites that are not
involved in membrane binding. In general, the free
epitopes will be available for antibody binding, whereas
the membrane-associated epitopes are shielded and will
not be accessible. The antibodies recognizing different
epitopes in different domains of the protein were used. As
negative controls, sandwich ELISA using 8860-ESH5
antibodies, both recognizing heavy chain epitopes, was
carried out. 8860 recognizes an epitope in the A2 domain,
whereas ESH5 recognizes an epitope in the a1 region.
Consistent with the model proposed by Stoilova-McPhie
et al. [8], the binding of FVIII to membranes did not
inhibit its interaction with these antibodies (data not
shown). However, the ELISA studies using C2 domain-
specific antibodies ESH4/ESH8 (biotinylated) displayed a
large (f 50%) reduction in binding of the membrane-
associated FVIII relative to FVIII. (Fig. 6). The ESH8
recognizes epitope 2248–2285, whereas ESH4 antibody
recognizes lipid-binding epitope (2303–2332) of the C2
domain (Fig. 1a) [29]. The results indicate that the
binding of either or both ESH4 and ESH8 is inhibited
by membrane interaction suggesting the participation of
2303–2332 and 2248–2285 in membrane binding. How-
ever, a complete inhibition of binding was not observed,
probably due to the existence of a small fraction of free
protein due to complex association/dissociation process
(see footnote 1) or antibody-mediated release of FVIII
from membranes.Saenko et al. [30] have shown ESH8-mediated inhibi-
tion of FVIII activity is not due to the reduced binding of
FVIII to membranes. This observation implies that the
epitope region recognized by ESH8 is not involved in
membrane binding. This corroborates with our control
sandwich ELISA studies using 8860-ESH8 antibodies, in
which no reduction in antibody binding was observed for
membrane-associated FVIII (data not shown). However, the
putative membrane binding amino acid residues, 2249–
2255 in this epitope region, may not be essential for
antibody binding.
In conclusion, FVIII interaction with membranes in-
volves minimal conformational change due to the involve-
ment of few amino acids in the C2 domain as the primary
contact between the protein and the membrane. These
observations are consistent with the model proposed
by electron crystallographic and biochemical studies
[8,22,23,31]. Additionally, the Stern–Volmer plots and
sandwich ELISA provide evidence for the involvement of
Trp-2313 localized in lipid binding domain in membrane
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